Monday, March 3rd, 2008
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Pfizer's chemotherapy agent, Camptosar(R) (Irinotecan Hydrochloride) Injection, 20 mg/mL. Shipment of this product, available in 40 mg/2 mL ...
Posted in Pharma Industry | No Comments »
Tuesday, February 26th, 2008
Antisense Therapeutics Limited (ASX: ANP) announced that the Company is scheduled to present at Sachs Associates 7th Annual North America Forum for Investing and Partnering in Biotech taking place on February 25-26 in Boston at the Fairmont Copley Plaza.
Mark Diamond, Antisense Therapeutics Chief Executive Officer, will give a presentation on ...
Posted in Pharma Industry | No Comments »
Monday, February 25th, 2008
Antiretroviral drugs are becoming a "growing profit center" for the pharmaceutical industry as treatment for HIV-positive people worldwide improves, the Los Angeles Times reports.
According to the Times, sales of antiretrovirals for Gilead Sciences, which sells antiretrovirals to about one half of all HIV-positive people taking drugs nationwide, reached $3.14 billion ...
Posted in HIV / AIDS | No Comments »
Monday, February 25th, 2008
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has received notification of European Patent Office (EPO) approval for technology to which Corgenix holds exclusive worldwide licensing rights.
McMaster University (McMaster) of Hamilton, Ontario, is the owner of the patent covering the aspirin resistance measurement method. ...
Posted in Medical Devices | No Comments »
Monday, February 25th, 2008
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced the receipt of a positive opinion from the CHMP, the scientific committee of the European Medicines Agency ("EMEA"), for its human granulocyte colony stimulating factor ("G-CSF") product. Teva's product is the first biosimilar G-CSF to receive a positive opinion in the European Union.
The ...
Posted in Pharma Industry | No Comments »
Saturday, February 23rd, 2008
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced the acceptance of an abstract describing the results of a study using Xibrom(TM) (bromfenac ophthalmic solution) 0.09% therapy in combination with Lucentis(R) (ranibizumab injection) in patients with age-related macular degeneration (AMD). According to the abstract, patients who received Xibrom required 1.6 +/- 0.69 injections ...
Posted in Eye Health / Optometry | No Comments »
Saturday, February 23rd, 2008
An article published on bmj.com claims that drug companies are still directly sponsoring the education of thousands of general practitioners. The Australian investigation is reported while the world is calling for an end to direct sponsorship by drug companies.
In Australia, it is common for drug company sponsors to recommend speakers ...
Posted in Medical Students | No Comments »
Friday, February 22nd, 2008
An article published on bmj.com claims that drug companies are still directly sponsoring the education of thousands of general practitioners. The Australian investigation is reported while the world is calling for an end to direct sponsorship by drug companies.
In Australia, it is common for drug company sponsors to recommend speakers ...
Posted in Medical Students | No Comments »
Friday, February 22nd, 2008
The prices of brand-name medications have continued to increase despite calls from all three major presidential candidates for pharmaceutical companies to make their products more affordable, the Wall Street Journal reports. Wholesale prices for the 50 brand-name medications with the most sales increased by an average of 7.82% in 2007, ...
Posted in Pharma Industry | No Comments »
